Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADIL Adial Pharmaceuticals

Pre-Mkt 05-06 06:39:36 EDT

1.60

+0.00

0.00%

盘前1.58

-0.02-1.25%

06:30 EDT

High1.64	Low1.58	Vol58.82K
Open1.60	D1 Closing1.60	Amplitude3.74%
Mkt Cap2.28M	Tradable Cap2.10M	Total Shares1.43M
T/O94.72K	T/O Rate4.49%	Tradable Shares1.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADIL","market":"US","secType":"STK","nameCN":"Adial Pharmaceuticals","latestPrice":1.6,"timestamp":1778011200000,"preClose":1.6,"halted":0,"volume":58817,"hourTrading":{"tag":"盘前","latestPrice":1.58,"preClose":1.6,"latestTime":"06:30 EDT","volume":1058,"amount":1683.580059,"timestamp":1778063448492,"change":-0.02,"changeRate":-0.0125,"amplitude":0.03125},"delay":0,"changeRate":0,"floatShares":1310700,"shares":1428000,"eps":-11.93062,"marketStatus":"Pre-Mkt","change":0,"latestTime":"05-06 06:39:36 EDT","open":1.6,"high":1.6399,"low":1.58,"amount":94723.5374613,"amplitude":0.037437,"askPrice":1.58,"askSize":83,"bidPrice":1.52,"bidSize":126,"shortable":3,"etf":0,"ttmEps":-11.93062,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778074200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1532664000000,"exchange":"NASDAQ","adjPreClose":1.6,"preHourTrading":{"tag":"盘前","latestPrice":1.58,"preClose":1.6,"latestTime":"06:30 EDT","volume":1058,"amount":1683.580059,"timestamp":1778063448492,"change":-0.02,"changeRate":-0.0125,"amplitude":0.03125},"postHourTrading":{"tag":"盘后","latestPrice":1.6,"preClose":1.6,"latestTime":"19:21 EDT","volume":128,"amount":204,"timestamp":1778023299183,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6729595135935894,"impliedVol":1.6275,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ADIL/tweets","defaultTab":"tweets","newsList":[{"id":"2631699544","title":"Adial Pharmaceuticals files AD04 utility application with USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2631699544","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631699544?lang=en_us&edition=fundamental","pubTime":"2026-04-30 00:56","pubTimestamp":1777481768,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (ADIL) announced the filing of a new U.S. utility application with the United States Patent and Trade Office, or USPTO, direc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-files-ad04-utility-application-with-uspto-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-files-ad04-utility-application-with-uspto-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631512662","title":"Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2631512662","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631512662?lang=en_us&edition=fundamental","pubTime":"2026-04-29 21:07","pubTimestamp":1777468020,"startTime":"0","endTime":"0","summary":"New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approachGLEN ALLEN, Va., ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283847/26135/en/Adial-Pharmaceuticals-Advances-IP-Portfolio-with-New-U-S-Utility-Patent-Application-Positioning-for-Potential-Market-Exclusivity-Through-2045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4136","ADIL","LU1169590202.USD","BK4007","IP","BK4588","LU1169589451.USD","IE00B3T34201.USD","LU1481599808.USD","LU1487256676.USD","LU1481600234.SGD","LU2463526074.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630391137","title":"Adial submits AD04 application for FDA Commissioner's National Priority Voucher pilot program","url":"https://stock-news.laohu8.com/highlight/detail?id=2630391137","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630391137?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:47","pubTimestamp":1777294035,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals submitted an application to FDA Commissioner’s National Priority Voucher  pilot program for its AD04 development program.CNPV, if granted, could allow an accelerated FDA review timeline of about 1-2 months once complete materials are submitted, versus standard 10-12 months.Voucher, if awarded, cannot be transferred or sold.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL9pbCDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2W23.USD","ADIL","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","BK4112","SG9999014039.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629475770","title":"Adial Pharmaceuticals completes AD04 demonstration batch production","url":"https://stock-news.laohu8.com/highlight/detail?id=2629475770","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629475770?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:57","pubTimestamp":1776866276,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (ADIL) announced completion of the demonstration batch production for AD04. The results of the batch confirmed that the trans...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-completes-ad04-demonstration-batch-production-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-completes-ad04-demonstration-batch-production-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629304237","title":"Adial completes AD04 demo batch, clearing path for planned Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629304237","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629304237?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:35","pubTimestamp":1776864931,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals completed manufacturing of a demonstration batch for its AD04 drug candidate, clearing a key step toward a planned Phase 3 clinical trial in Alcohol Use Disorder.Results have already been generated from the batch work, showing process performance consistent with prior Phase 2 production.The outcome supports production of clinical and registration batches, which Adial expects to use to advance trial execution and update its IND with FDA.Adial is planning a new Phase 3 program targeting patients selected with its proprietary genetic test, following earlier ONWARD findings that indicated potential benefit without new safety or tolerability concerns.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLNfzwk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014021.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","BK4585","ADIL","LU2210149790.SGD","BK4588","LU2095319765.USD","LU0314104364.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4007","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4112","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626153030","title":"Adial Pharmaceuticals Implements New Executive Equity Compensation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2626153030","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626153030?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:37","pubTimestamp":1775770649,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals ( ($ADIL) ) just unveiled an announcement. On April 7, 2026, Adial Pharmaceuticals’ Compensation Committee approved grants of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adial-pharmaceuticals-implements-new-executive-equity-compensation-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adial-pharmaceuticals-implements-new-executive-equity-compensation-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","BK4585","BK4215","EQR","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626158242","title":"Adial Pharma grants CEO Cary Claiborne 37,985 restricted stock awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2626158242","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626158242?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:01","pubTimestamp":1775768515,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals granted restricted stock awards on April 7, 2026, covering 37,985 shares to CEO Cary Claiborne.Restricted shares vest in full on earlier of one-year anniversary of grant date or change of control.Director compensation included 9,185 restricted shares each for Kevin Schuyler, Robertson H. Gilliland; Kermit Anderson received options for 9,185 shares at USD 1.64 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL212hFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067075","title":"Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067075","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067075?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:07","pubTimestamp":1774357636,"startTime":"0","endTime":"0","summary":"Adial commented on the introduction of H.R. 7091, the Expanding Veterans' Access to Emerging Treatments Act, which would expand research and development of emerging therapies for veterans, including Alcohol Use Disorder.The company said the bill supports investigational therapies aligned with an updated federal definition of recovery that includes non-abstinence based treatment options.Adial stated that its lead investigational candidate, AD04, is being developed as a genetically targeted, non-abstinence based therapy for Alcohol Use Disorder.The company noted the bill has been referred to the House Committee on Veterans' Affairs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7kMs5l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4007","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2210149790.SGD","NDAQ","BK4588","BK4112","IE00BGHQF748.EUR","ADIL","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617388426","title":"Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617388426","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617388426?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:07","pubTimestamp":1772802447,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51093306/adial-pharmaceuticals-q4-eps-11-48-misses-0-09-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617680733","title":"Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680733?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:00","pubTimestamp":1772802000,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., March 06, 2026  --  Adial Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025.-- Achieved positive clinical study results from the AD04-103. -- Received a positive response from the U.S. Food and Drug. core assets and extend international exclusivity by 14 years. supply in support of late-stage development and future. \"2025 was a pivotal year for Adial as we continued to advance AD04 scientifically, strategically, and within an evolving regulatory landscape,\" said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. \"Our positive AD04-103 pharmacokinetic results, productive End-of-Phase 2 meeting with the FDA, and supportive FDA feedback on our in vitro bridging strategy provided meaningful validation of our clinical and regul","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","PCT","ADIL","BK4218","BK4007","BK4181","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617602577","title":"Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617602577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617602577?lang=en_us&edition=fundamental","pubTime":"2026-03-06 07:46","pubTimestamp":1772754374,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryAdial Pharmaceuticals Inc ADIL.OQ reported a quarterly adjusted loss of $3.07 per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT33L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617257111","title":"Adial Pharma posts FY 2025 net loss of USD 8.0 million, down 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617257111","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617257111?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:04","pubTimestamp":1772748256,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbK0qB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616323495","title":"Adial Pharmaceuticals enters collaboration framework agreement with Molteni","url":"https://stock-news.laohu8.com/highlight/detail?id=2616323495","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616323495?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:35","pubTimestamp":1772544920,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (ADIL) announced it has entered into a collaboration framework agreement with Molteni Farmaceutici for a proposed exclusive p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-enters-collaboration-framework-agreement-with-molteni-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-enters-collaboration-framework-agreement-with-molteni-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616328122","title":"Adial Pharmaceuticals Signs Exclusive AD04 Collaboration Framework With Molteni for Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2616328122","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616328122?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:17","pubTimestamp":1772543836,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals has signed an exclusive collaboration framework with Molteni Farmaceutici to pursue a potential partnership to commercialize AD04 in Europe, with Molteni granted exclusivity to conduct planning and due diligence ahead of a definitive agreement. The planned deal is expected to include an upfront payment, development and commercial milestones, and tiered royalties, with total potential royalties and milestones estimated at nearly $60 million if AD04 advances successfully.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDLbkqxP4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","ADIL","BK4007","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4585","NDAQ","BK4112","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616281203","title":"Adial Pharmaceuticals Inc: Engaging With Potential Commercial Partners in United States, to Initiate Its Pivotal Phase 3 Program in Near Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2616281203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616281203?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:17","pubTimestamp":1772543820,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA3ZW9VV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616232814","title":"Adial Pharmaceuticals Signs an Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici for Europe Which Anticipates Nearly $60 Million in Potential Royalties and Milestones Upon Execution of a Definitive Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2616232814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616232814?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:17","pubTimestamp":1772543820,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA3ZW9VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616287383","title":"EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616287383","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616287383?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542920,"startTime":"0","endTime":"0","summary":"Adial Pharma signs Europe deal with Molteni for AD04, eyeing up to $60 million in milestones and royalties.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/03/ADIL.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/03/ADIL.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/50996572/exclusive-adial-pharma-eyes-europe-deal-for-lead-drug-for-alcohol-use-disrder-worth-up-to-60-million","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/50996572/exclusive-adial-pharma-eyes-europe-deal-for-lead-drug-for-alcohol-use-disrder-worth-up-to-60-million","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614859258","title":"Adial Pharmaceuticals Inc  expected to post a loss of $2.15 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859258","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859258?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:49","pubTimestamp":1772200145,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals Inc  expected to post a loss of $2.15 a share - Earnings Preview Adial Pharmaceuticals Inc ADIL.OQ ADIL.O is expected to  show no change in quarterly revenue when it reports  res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN1KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613175067","title":"BRIEF-Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2613175067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613175067?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:06","pubTimestamp":1771941966,"startTime":"0","endTime":"0","summary":"BRIEF-Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing RequirementFeb 24 (Reuters) - Adial Pharmaceuticals Inc ADIL.O:ADIAL PHARMACEUTICALS REGAINS FULL COMPLIANCE WITH NASDAQ LISTING","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA4PJTNJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613171784","title":"Adial Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2613171784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613171784?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941714,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals said it has resolved a Nasdaq regulatory listing issue after receiving notice that it regained compliance with Nasdaq’s minimum bid price rule. Nasdaq determined the company’s shares closed at or above $1.00 for 10 consecutive business days, and the exchange has closed the matter.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL5wcqd4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","ADIL","BK4007","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4585","NDAQ","BK4112","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adialpharma.com","stockEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.5918},{"period":"6month","weight":-0.8043},{"period":"1year","weight":-0.9072},{"period":"ytd","weight":-0.7091}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.058856},{"month":2,"riseRate":0.25,"avgChangeRate":-0.031808},{"month":3,"riseRate":0,"avgChangeRate":-0.155549},{"month":4,"riseRate":0.375,"avgChangeRate":-0.03424},{"month":5,"riseRate":0.375,"avgChangeRate":-0.067558},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.158497},{"month":7,"riseRate":0.571429,"avgChangeRate":0.080123},{"month":8,"riseRate":0.125,"avgChangeRate":-0.073571},{"month":9,"riseRate":0.375,"avgChangeRate":-0.037962},{"month":10,"riseRate":0.25,"avgChangeRate":-0.152838},{"month":11,"riseRate":0.375,"avgChangeRate":0.139286},{"month":12,"riseRate":0.375,"avgChangeRate":0.00671}],"exchange":"NASDAQ","name":"Adial Pharmaceuticals","nameEN":"Adial Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adial Pharmaceuticals,ADIL,Adial Pharmaceuticals股票,Adial Pharmaceuticals股票老虎,Adial Pharmaceuticals股票老虎国际,Adial Pharmaceuticals行情,Adial Pharmaceuticals股票行情,Adial Pharmaceuticals股价,Adial Pharmaceuticals股市,Adial Pharmaceuticals股票价格,Adial Pharmaceuticals股票交易,Adial Pharmaceuticals股票购买,Adial Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}